FLOXIN
LOE ApproachingNDAORALTABLET
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FLOXIN is an oral small-molecule tablet approved in 1990 by Johnson & Johnson. The specific indication and mechanism of action are not disclosed in available data. Patients using this product represent a mature market segment established over three decades.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); commercial team focus is likely on brand defense and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children
Started Nov 2002
96 enrolled
Otitis Media
Career Relevance
FLOXIN currently has zero linked job openings, reflecting its mature, stable market position with limited expansion. Career opportunities are concentrated in brand defense, channel management, and LOE transition planning rather than innovation.
Brand Manager
Worked on FLOXIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.